10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy-Reference-Cited by-同舟云学术

10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy

Published:2001-09 Issue:1 Volume:51 Page:31-40
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Grimm Peter D,Blasko John C,Sylvester John E,Meier Robert M,Cavanagh William

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference13 articles.

1. Ultrasound-guided transperineal implantation of Iodine-125 and Palladium-103 for the treatment of early-stage prostate cancer;Grimm,1994

2. Manual for staging of cancer,1992

3. Consensus statement. Guidelines for PSA following radiation therapy;Int J Radiat Oncol Biol Phys,1997

4. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer;Zelefsky;Int J Radiat Oncol Biol Phys,1998

5. Transient elevation of serum prostate-specific antigen following 125I/103Pd brachytherapy for localized prostate cancer;Cavanagh;Semin Urol Oncol,2000

Cited by 400 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of phosphorus-32 microparticle intratumoral implantation added to chemotherapy in patients with metastatic pancreatic adenocarcinoma;iGIE;2024-07

2. Overview of Radiation Therapy in the Management of Localized and Metastatic Prostate Cancer;Current Urology Reports;2024-06-11

3. Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up;Brachytherapy;2024-05

4. Unfavorable Intermediate- and High-Risk Prostate Cancer Treated With Predominantly Brachytherapy Alone With Long-Term Follow-Up;Applied Radiation Oncology;2023-12-01

5. Associations of Clinical and Dosimetric Parameters with Urinary Toxicities after Prostate Brachytherapy: A Long-Term Single-Institution Experience;Current Oncology;2023-06-09